LCTX · AMEX
Lineage Cell Therapeutics (LCTX) Stock Price & Fundamentals
Lineage Cell Therapeutics (LCTX) closed at $688.44 on Oct 9, 2026, down 1.67% from the previous close of $700.11.
Share price, past year
1Y +31.99%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $688.44 |
| Sep 30, 2026 | $703.90 |
| Aug 31, 2026 | $734.39 |
| Jul 31, 2026 | $742.07 |
| Jun 30, 2026 | $715.90 |
| May 29, 2026 | $700.27 |
| Apr 30, 2026 | $679.69 |
| Mar 31, 2026 | $623.14 |
| Feb 27, 2026 | $598.57 |
| Jan 30, 2026 | $588.94 |
| Dec 31, 2025 | $569.12 |
| Nov 28, 2025 | $547.46 |
| Oct 31, 2025 | $516.38 |
Key statistics
- Market cap
- $174.11B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.19
- Revenue (TTM)
- $13.08M
- Net income (TTM)
- −$32.26M
- Shares outstanding
- 252.9M
- Dividend yield
- —
- 52-week range
- $515.82 – $755.17
Lineage Cell Therapeutics's market cap is $174.11B, based on a share price of $688.44 and 252.9M shares outstanding as of Jun 30, 2026.
Financials
Lineage Cell Therapeutics reported revenue of $14.56M for fiscal 2025, up 53.24% from fiscal 2024.
Lineage Cell Therapeutics reported a net loss of $63.53M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $14.56M | +53.2% | −$63.53M | −436.5% | −$0.28 | −$19.44M |
| FY2024ended Dec 31, 2024 | $9.50M | +6.2% | −$18.61M | −195.9% | −$0.09 | −$23.66M |
| FY2023ended Dec 31, 2023 | $8.95M | −39.2% | −$21.49M | −240.2% | −$0.12 | −$29.24M |
| FY2022ended Dec 31, 2022 | $14.70M | +238.7% | −$26.27M | −178.7% | −$0.15 | $646.00K |
| FY2021ended Dec 31, 2021 | $4.34M | +137.7% | −$43.02M | −991.0% | −$0.26 | −$23.90M |
| FY2020ended Dec 31, 2020 | $1.83M | −48.1% | −$20.65M | −1,130.8% | −$0.14 | −$19.82M |
| FY2019ended Dec 31, 2019 | $3.52M | −29.5% | −$11.71M | −333.1% | −$0.08 | −$32.39M |
| FY2018ended Dec 31, 2018 | $4.99M | +44.3% | −$45.99M | −922.0% | −$0.36 | −$31.44M |
| FY2017ended Dec 31, 2017 | $3.46M | −41.6% | −$19.98M | −577.7% | −$0.17 | −$31.84M |
| FY2016ended Dec 31, 2016 | $5.92M | — | $33.57M | 566.8% | $0.34 | −$44.57M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $1.07M | $1.48M | −$0.03 |
| Q1 FY2026ended Mar 31, 2026 | $1.73M | −$4.81M | −$0.03 |
| Q4 FY2025ended Dec 31, 2025 | $6.61M | $851.00K | $0.00 |
| Q3 FY2025ended Sep 30, 2025 | $3.68M | −$29.78M | −$0.13 |
| Q2 FY2025ended Jun 30, 2025 | $2.77M | −$30.46M | −$0.13 |
| Q1 FY2025ended Mar 31, 2025 | $1.50M | −$4.14M | −$0.02 |
| Q4 FY2024ended Dec 31, 2024 | $2.87M | −$3.27M | $0.00 |
| Q3 FY2024ended Sep 30, 2024 | $3.78M | −$3.03M | −$0.02 |
Company profile
- Name
- Lineage Cell Therapeutics, Inc.
- Ticker
- LCTX
- Exchange
- AMEX
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008
- Incorporated in
- CA
- Fiscal year ends
- December
- SEC CIK
- 0000876343
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jun 12, 2026
- May 12, 2026
- May 12, 2026
- Mar 11, 2026
- Mar 5, 2026
- Mar 5, 2026
Frequently asked questions
What is Lineage Cell Therapeutics's stock price?
Lineage Cell Therapeutics (LCTX) closed at $688.44 on Oct 9, 2026, down 1.67% from the previous close of $700.11.
What is Lineage Cell Therapeutics's market cap?
Lineage Cell Therapeutics's market cap is $174.11B, based on a share price of $688.44 and 252.9M shares outstanding as of Jun 30, 2026.
How much revenue does Lineage Cell Therapeutics make?
Lineage Cell Therapeutics reported revenue of $14.56M for fiscal 2025, up 53.24% from fiscal 2024.
Does Lineage Cell Therapeutics pay a dividend?
Lineage Cell Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Lineage Cell Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures